H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Apellis Pharmaceuticals today and set a price target of $57.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Douglas Tsao has given his Buy rating due to a combination of factors that highlight the potential of Apellis Pharmaceuticals. The recent approval of Empaveli with a broad label for treating C3G and Primary IC-MPGN in patients aged 12 and older positions it as a new standard of care. Empaveli’s unique FDA label, which includes key efficacy endpoints such as proteinuria reduction, stabilization of kidney function, and clearance of C3 deposits, distinguishes it from competitors like Fabhalta. This approval is expected to drive physician interest and patient identification, bolstered by compelling clinical data.
Furthermore, Apellis has prepared its market access and sales teams for the launch of Empaveli, aiming to capture a significant portion of the estimated 5,000 C3G and primary IC-MPGN patients in the US. With a price target of $57, Tsao’s valuation considers the potential for Apellis’ revenues to exceed $1 billion, driven by Empaveli and Syfovre. The valuation is based on a risk-adjusted revenue estimate, with key risks including regulatory approvals and potential competition from emerging technologies. Overall, the attractive valuation and growth prospects underpin the Buy rating.
Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Argenx Se, and Crinetics Pharmaceuticals. According to TipRanks, Tsao has an average return of 12.7% and a 46.28% success rate on recommended stocks.